News der MEDICE Health Family

Selected category: Healthcare solutions

Announcements, Corporate, Nephrology, Healthcare solutions

10.08.2026

MEDICE Renal Care at Nephro Update Europe 2026 in Prague

MEDICE will participate in Nephro Update Europe for the second time in 2026. The two-day scientific congress will take place on September 11 and 12, 2026, in Prague and online, providing healthcare professionals with a concise overview of the latest developments in nephrology.

News Thumbnail

Healthcare solutions, Nephrology

05.08.2026

Positive Results from the VOICE Study for Vafseo® in Dialysis Patients with CKD-Related Anaemia

Positive results from the VOICE study have been published for Vafseo® (vadadustat), a medicine from the MEDICE Health Family for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD). Conducted by U.S. Renal Care (USRC) and Akebia Therapeutics, the study evaluated the safety and efficacy of administering Vafseo® three times weekly in patients with end-stage kidney disease receiving haemodialysis in dialysis centres.

News Thumbnail

Announcements, Corporate, Nephrology, Healthcare solutions

08.06.2026

ERA 2026 in Glasgow: International Exchange Driving the Future of Nephrology

The ERA Congress 2026 in Glasgow once again underscored its role as one of the leading international platforms for scientific exchange in nephrology. With a record attendance of 10,670 participants, this year's congress brought together experts from academia, clinical practice, and industry from around the world.

News Thumbnail

Announcements, Corporate, Healthcare solutions, Cold, Product, OTC

19.01.2026

Launch of Meditonsin Extract: Triple the plant power shortens the duration of a cold

Just in time for the current wave of colds, MEDICE is bringing a herbal cold remedy to pharmacies: Meditonsin Extract. Scientifically proven, it offers a clear advantage—it shortens the duration of the cold.

News Thumbnail

Announcements, ADHD, Healthcare solutions, Corporate

15.08.2025

attexis® – die erste dauerhaft gelistete DiGA für Erwachsene mit ADHS

Mit attexis® steht ab sofort eine klinisch wirksame und extrabudgetär verordnungsfähige Therapie für Erwachsene mit einer ADHS zur Verfügung.

News Thumbnail